Harvest Fund Management Co. Ltd Decreases Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO)

Harvest Fund Management Co. Ltd decreased its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 77.7% in the fourth quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 119 shares of the medical research company’s stock after selling 415 shares during the period. Harvest Fund Management Co. Ltd’s holdings in Thermo Fisher Scientific were worth $62,000 as of its most recent SEC filing.

A number of other large investors also recently added to or reduced their stakes in the business. Vinva Investment Management Ltd increased its holdings in shares of Thermo Fisher Scientific by 8.2% in the fourth quarter. Vinva Investment Management Ltd now owns 19,824 shares of the medical research company’s stock worth $10,285,000 after buying an additional 1,502 shares during the period. Stokes Family Office LLC purchased a new position in Thermo Fisher Scientific in the 4th quarter worth approximately $410,000. VSM Wealth Advisory LLC purchased a new stake in shares of Thermo Fisher Scientific during the fourth quarter valued at approximately $36,000. OVERSEA CHINESE BANKING Corp Ltd grew its holdings in shares of Thermo Fisher Scientific by 48.3% in the fourth quarter. OVERSEA CHINESE BANKING Corp Ltd now owns 7,908 shares of the medical research company’s stock worth $4,114,000 after purchasing an additional 2,576 shares during the last quarter. Finally, Brooklyn FI LLC purchased a new position in shares of Thermo Fisher Scientific in the fourth quarter worth $633,000. Hedge funds and other institutional investors own 89.23% of the company’s stock.

Thermo Fisher Scientific Stock Down 0.1 %

Shares of Thermo Fisher Scientific stock opened at $518.04 on Monday. The company has a 50-day simple moving average of $546.15 and a two-hundred day simple moving average of $555.52. Thermo Fisher Scientific Inc. has a 52-week low of $493.30 and a 52-week high of $627.88. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.29 and a current ratio of 1.66. The stock has a market capitalization of $195.44 billion, a PE ratio of 31.34, a price-to-earnings-growth ratio of 2.99 and a beta of 0.79.

Thermo Fisher Scientific (NYSE:TMO) last issued its earnings results on Thursday, January 30th. The medical research company reported $6.10 EPS for the quarter, beating the consensus estimate of $5.94 by $0.16. Thermo Fisher Scientific had a return on equity of 17.51% and a net margin of 14.78%. On average, analysts anticipate that Thermo Fisher Scientific Inc. will post 23.28 EPS for the current fiscal year.

Thermo Fisher Scientific Increases Dividend

The business also recently declared a quarterly dividend, which will be paid on Tuesday, April 15th. Stockholders of record on Friday, March 14th will be issued a dividend of $0.43 per share. This represents a $1.72 dividend on an annualized basis and a dividend yield of 0.33%. The ex-dividend date of this dividend is Friday, March 14th. This is an increase from Thermo Fisher Scientific’s previous quarterly dividend of $0.39. Thermo Fisher Scientific’s dividend payout ratio (DPR) is presently 10.41%.

Wall Street Analysts Forecast Growth

Several equities analysts have recently commented on TMO shares. Raymond James reaffirmed an “outperform” rating and set a $667.00 price objective (up from $650.00) on shares of Thermo Fisher Scientific in a research note on Monday, February 3rd. StockNews.com upgraded Thermo Fisher Scientific from a “hold” rating to a “buy” rating in a report on Tuesday, January 14th. Bank of America reduced their target price on Thermo Fisher Scientific from $675.00 to $660.00 and set a “buy” rating on the stock in a research note on Friday, December 13th. Wells Fargo & Company lifted their price target on shares of Thermo Fisher Scientific from $660.00 to $680.00 and gave the company an “overweight” rating in a report on Friday, January 31st. Finally, Sanford C. Bernstein upgraded shares of Thermo Fisher Scientific from a “market perform” rating to an “outperform” rating and set a $630.00 price objective for the company in a report on Friday, January 10th. Four investment analysts have rated the stock with a hold rating and nineteen have issued a buy rating to the stock. Based on data from MarketBeat, Thermo Fisher Scientific has an average rating of “Moderate Buy” and a consensus price target of $653.23.

Insider Transactions at Thermo Fisher Scientific

In other Thermo Fisher Scientific news, EVP Gianluca Pettiti sold 300 shares of the business’s stock in a transaction on Tuesday, February 4th. The shares were sold at an average price of $585.59, for a total transaction of $175,677.00. Following the completion of the sale, the executive vice president now directly owns 16,363 shares in the company, valued at approximately $9,582,009.17. The trade was a 1.80 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this hyperlink. Also, SVP Michael A. Boxer sold 3,775 shares of the firm’s stock in a transaction on Monday, March 10th. The stock was sold at an average price of $532.52, for a total value of $2,010,263.00. Following the completion of the transaction, the senior vice president now owns 10,816 shares in the company, valued at approximately $5,759,736.32. This trade represents a 25.87 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold 23,900 shares of company stock worth $13,106,062 over the last three months. 0.34% of the stock is currently owned by company insiders.

About Thermo Fisher Scientific

Thermo Fisher Scientific Inc provides life sciences solutions, analytical instruments, specialty diagnostics, and laboratory products and biopharma services in the North America, Europe, Asia-Pacific, and internationally. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery, and production of drugs and vaccines, as well as diagnosis of infections and diseases; and solutions include biosciences, genetic sciences, and bio production to pharmaceutical, biotechnology, agricultural, clinical, healthcare, academic, and government markets.